Background
Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell proliferation-induced myeloproliferative disease [
1]. Because of its high heterogeneity and distinct molecular genetic features, it has attracted extensive attention from researchers. The unique cytogenetic features of CML include the Philadelphia chromosome t (9; 22) (q34; q11), forming a BCR-ABL fusion gene; this gene complex encodes a constitutively active form of the BCR–ABL fusion tyrosine kinase protein. The active site of the tyrosine kinase has a binding site for ATP [
2]. Most signalling pathways activated by BCR-ABL are involved in promoting the development of cancer in bone marrow cells, including the Ras-MAPK pathway, the Src-Pax-Fak-Rac pathway, the phosphoinositide-3 kinase (PI3K)–Akt pathway, and the JAK-STAT pathway [
3‐
6].
The development of the tyrosine kinase inhibitor (TKI) imatinib represents a milestone in CML treatment. Imatinib binds specifically to the ATP-binding site of BCR-ABL to form a fusion protein complex, locking in the active site [
7]. This blocks CML cells whose active sites limit repeated cell growth and cell proliferation, killing the cancer cells. However, TKI treatment is long-term and induces resistance to TKI, often leading to poor clinical outcomes in CML patients. Drug resistance to TKIs is currently a clinical problem for CML. It isvery importantto find a strategy to inhibit imatinib resistance.
Classical traditional Chinese medicine (TCM) in China has been used for thousands of years. Especially in recent years, Chinese medicine has made some progress in the treatment of cancer. For example, Bu-Zhong-Yi-Qi-Decoction (BZYQD) has been reported to induce gastric cancer cell death by nonapoptotic mechanisms and to induce human ovarian cancer cell death by apoptotic mechanisms [
8,
9]. Yu Ning, et al., through the combination BZYQD with cisplatin in cisplatin-resistant A549/DDP cells, showed that BZYQD exhibited direct cytotoxic and chemosensitising effects, suggesting that cotreatment with BZYQD and cisplatin might reverse cisplatin resistance by inducing ROS accumulation, activating apoptosis and autophagy by oxidative stress [
10]. It was reported that Qingdai acted on a variety of pathways for the treatment of chronic myeloid leukaemia, including cytokine-cytokine receptor interaction, cell cycle, p53 signalling pathway, MAPK signalling pathway, and immune system-related pathways [
11]. Indirubin is the most important and valuable compound in Qingdai; it has been determined to be the quality marker of Qingdai in the Chinese Pharmacopoeia (the State Pharmacopoeia Commission of China, 2015). Studies showed that indirubin and its derivatives inhibited imatinib resistance. For example, the AGM130 compound, derived from indirubin, known as a cyclin-dependent kinase inhibitor, was a strong candidate for treating imatinib-resistant CML [
12]. Therefore, in this study, we will use the strategy of ‘Drug Target Prediction-Gene Microarray Analysis-Protein Network Construction’ to explore the mechanism of indirubin and its derivatives in inhibiting imatinib resistance.
Discussion
Qingdai is a traditional Chinese medicine used to treat CML; it is the major active TCM of Qing-Huang-San [
27], a Chinese traditional medicine used for the treatment of CML symptoms. It has been widely used in China and has achieved good clinical results. Indirubin is the major active component of Qingdai. Numerous studies have shown that indirubin and its derivatives not only promote apoptosis of CML cells but also inhibit imatinib resistance, including indirubin, indirubin derivative E804, and indirubin-3-acetoxime [
28‐
30]. The exact mechanism of action remains unclear. Therefore, We used the Drug Target Prediction-Gene Microarray Analysis-Protein Network Construction model to investigate the mechanism by which indirubin and its derivatives inhibit imatinib resistance. Various methods, including indirubin derivative screening, drug target search screening, gene chip analysis, network construction, network target analysis, and molecular docking were combined to perform this study. A total of 42 small-molecule compounds were collected and predicted for putative targets. A total of 125 DEGs were selected for imatinib resistance. A total of 15 small-molecule compounds were found to inhibit imatinib resistance by 11 related genes. In our research, data mining of existing databases allows for the objective and rapid discovery of associations and identification of potential drug targets to facilitate the discovery of drugs that inhibit imatinib resistance.
CML is a major haematological malignancy. Imatinib is one of the primary drugs for the treatment of chronic myelogenous leukaemia; however, due to the resistance to imatinib, we were forced to study new drugs to inhibit the resistance to imatinib [
31]. Drug resistance involves multiple steps and multiple genes. Therefore, various studies have analysed the differences in gene expression in imatinib-resistant and non-resistant genes by genomic microarrays. In the present study, we performed Go analysis and KEGG analysis on 125 differentially expressed genes and found that the resistance to imatinib was closely related to the following signalling pathways: (1) cell cycle, cell transcription, proliferation, apoptosis, and angiogenesis-related pathways; (2) cytokine-cytokine receptor interaction and chemokine signalling pathways; (3) cancer system related pathways, including pathways in cancer, the p53 signalling pathway and Jak-STAT signalling; (4) the immune system signalling pathway, the T cell receptor signalling pathway, the Toll-like receptor signalling pathway and the NOD-like receptor signalling pathway.
By analysing DEGs, we found that individual genes can serve as biomarkers for imatinib resistance. In up-regulated DEGs, CCL-13, the most significant up-regulated DEGs, is a chemokine that induces eosinophilic chemicals [
32]; it can be involved in the interaction between haematopoietic stem cells and the bone marrow microenvironment [
33]. In addition, the cytokine-cytokine receptor and chemokine signalling pathways involved in CCL-13 are important pathways involved in imatinib resistance. MAPK11 is the second most prominently expressed gene in the up-regulated differentially expressed genes for imatinib resistance, and MAPK11 is an important constituent gene of the MAPK signalling pathway and is involved in the regulation of various angiogenesis-related diseases [
34]. The MAPK signalling pathway is significantlyaugmentedafter imatinib resistance and may be closely related to imatinib resistance. MAPK11 is also involved in up-regulating multiple regulatory pathways for DEGs, including the Toll-like receptor signalling pathway and leukocyte transendothelial migration. PIK3CD is involved in almost all pathways involved in the up-regulation of differentially expressed genes and is significantly augmentedin the course of imatinib resistance. Mesenchymal stem cells (MSC) from BM of chronic myeloid leukaemia (CML) patients on interaction with CML cells or its secreted factors, secreted high levels of IL6, providing a survival advantage to CML cells from imatinib-induced apoptosis [
35]; Thus, IL6 may contribute to CML immune escape. Moreover, IL6 is involved in the cytokine-cytokine receptor interaction, the Jak-STAT signalling pathway, and pathways in cancer; therefore, it is closely related to imatinib resistance.
In the down-regulated DEGs, CASP8, an apoptosis-related factor, is an important apoptosis-related gene. Investigators used quantitative PCR to study apoptotic gene expression profile before and after imatinib treatment; they suggested that apoptosis-related gene expression profiles were associated with primary resistance to imatinib [
36]. IL12A enhances cellular immunity in the treatment of CML. Studies have shown that immunotherapy enhanced the efficacy of imatinib, and low expression of IL12A led to immune escape of CML cells [
37]. Therefore, CCL13, MAPK11, PIK3CD, IL6, CASP8, and IL12A play an important role in the process of imatinib resistance and can be used as biomarkers for imatinib resistance.
To elucidate the relationship between indirubin and its derivatives and imatinib resistance, we constructed a P-P network [
38]. By analysing the P-P network, we found that there was a close relationship between the putative target of indirubin and its derivatives and DEGs of imatinib resistance. Through screening, we characterised a total of 11 putative targets [
39]. Indirubin and its derivatives may inhibit imatinib resistance through these 11 putative targets. Based on 11 putative targets, we screened 15 small molecule compounds.
Among the 11 putative targets, gefitinib, an EGFR inhibitor, was tested in combination with imatinib in K562 CML cell line using MTT cell proliferation assay and was found to have a synergistic antiproliferative activity; EGFR inhibits or reverses imatinib resistance by enhancing the ability of imatinib to bind at the ATP-binding site of Bcr-Abl kinase [
40]. The study found that JAK2 and JAK3 had antiproliferative effects on imatinib-resistant BCR-ABL(+) cells [
41], and the administration of imatinib plus a JAK inhibitor reduced expression of stem cells markers, enhancing the antitumour effects of imatinib in CML cells [
42]. Human ERBB2 is a proto-oncogene that codes for the erbB-2 epithelial growth factor receptor [
43]. CHUK plays an important role in the NF-κB signalling pathway; indirubin and its derivatives inhibited CML cell proliferation by inhibiting CHUK activation of the NF-κB signalling pathway [
44]. A study showed that NF-κB represents a potential target for molecular therapies in CML [
45]. KIF11 inhibited cell proliferation by blocking the cycle of CML cells. The data showed that KIF11 was overexpressed in BCR-ABL+ CML cells and may become a novel treatment agent for patients with CML [
46]. Administration of the imatinib plus JAK inhibitor reduces the expression of stem cell markers, such as ABCG2 and ALDH1A1. Blocking JAK3 with imatinib and JAK3 inhibitors may represent a new therapeutic strategy for eradicating LSCs and preventing CML recurrence [
47].
We Identified a total of 15 small-molecule compounds that showed potential inhibition or reversal of resistance to imatinib. Active indirubins might inhibit T315I Abl kinase through unprecedented binding to both active and Src-like inactive conformations [
30]. The AGM130 compound is derived from indirubin; data showed that the AGM130 compound efficiently decreased the viability of CML-derived K562 cells. Moreover, this compound also efficiently decreased the viability of imatinib-resistant CML cells in in vitro and in vivo systems [
5]. E804, the most potent in indirubin derivative, blocked Stat5 signalling in human K562 CML cells, inhibiting the SFK/Stat5 signalling pathway downstream of Bcr-Abl, leading to apoptosis of K562, KCL-22 M and primary CML cells [
48]. In the present study, we Identified small-molecule compounds of indirubin and its derivatives that could potentially inhibit imatinib resistance through drug target prediction, gene microarray analysis, and network construction, accelerating the discovery of new drugs for the treatment of imatinib resistance.
Finally, we used computer simulation techniques to dock selected small-molecule compounds to putative targets, and docking scores showed meaningful results, indicating that our series of strategies can achieve the desired results.